PRECLINICAL AND CLINICAL STUDIES - Pharmaceutical Amorphous Solid Dispersions - page 307

6. Gardner, C., Walsh, C., and Almarsson, Ö. (2004) Drugs as materials: valuing physical form
in drug discovery. Nat. Rev. Drug Discov. , 3:926-934.
7. Huang, L. and Tong, W. (2004) Impact of solid state properties on druggability assessment of
drug candidates. Adv. Drug Deliv. Rev. , 56:321-334.
8. Lipinski, C. and Hopkins, A. (2004) Navigating chemical space for biology and medicine.
Nature , 432:855-862.
9. Gashaw, I., Ellinghaus, P., Sommer, A., and Asadullah, K. (2011) What makes a good drug
target? Drug Discov. Today , 16:1037

1043.
10. Blagden, N., de Matas, M., Gavan, P., and York, P. (2007) Crystal engineering of active
pharmaceutical ingredients to improve solubility and dissolution rate. Adv. Drug Deliv. Rev. ,
59:617-630.
11. Liu, R. (Ed.), (2008) Water-Insoluble Drug Formulations , CRC Press, Boca Raton, FL.
12. Pinnamaneni, S., Das, N., and Das, S. (2002) Formulation approaches for orally administered
poorly soluble drugs. Die Pharm. , 57:291-300.
13. Kawabata, Y., Wada, K., Nakatani, M., Yamada, S., and Onoue, S. (2011) Formulation
design of poorly water-soluble drugs based on biopharmaceutics classification system: basic
approaches and practical applications. Int. J. Pharm. , 420:1-10.
14. Williams, R., Watts, A., and Miller, D. (Eds.), (2012) Formulating Poorly Water Soluble
Drugs , Springer, Arlington, VA.
15. Loftsson, T. and Brewster, M. (1996) Pharmaceutical applications of cyclodextrins: I. Drug
solubilization and stabilization. J. Pharm. Sci. , 85:1017-1025.
16. Davis, M. E. and Brewster, M. E. (2004) Cyclodextrin-based pharmaceutics: past, present,
future. Nat. Rev. Drug Discov. , 3:1023-1035.
17. Brewster, M. and Loftsson, T. (2007) Cyclodextrins as pharmaceutical solubilizers. Adv.
Drug Deliv. Rev. , 59:645-666.
18. Loftsson, T. and Brewster, M. (2010) Pharmaceutical applications of cyclodextrins: basics
science and product development. J. Pharm. Pharmacol. , 62:1607-1621.
19. Loftsson, T. and Brewster, M. (2011) Pharmaceutical applications of cyclodextrins: effects
on drug permeation through biological membranes. J. Pharm. Pharmacol. , 63:1119-1135.
20. Strickley, R. (2004) Solubilizing excipients in oral and injectable formulations. Pharm. Res. ,
21:201-230.
21. Miller, J., Beig, A., Carr, A., Webster, G., and Dahan, A. (2012) The solubility-permeability
interplay when using cosolvents for solubilization: revising the way we use solubility-
enabling formulations. Mol. Pharm. , 9:581-590.
22. Porter, C., Trevaskis, N., and Charman, W. (2007) Lipid and lipid-based formulations:
optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. , 6:231-248.
23. Hauss, D. (2007) Oral lipid-based formulations. Adv. Drug Deliv. Rev. , 59:667-676.
24. O'Driscoll, C. and Griffin, B. (2008) Biopharmaceutical challenges associated with drugs
with low aqueous solubilities: the potential impact of lipid-based formulations. Adv. Drug
Deliv. Rev. , 60:617-624.
25. Dahan, A. and Hoffman, A. (2007) The effect of different lipid-based formulations on the oral
absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo
intestinal permeability to predict in vivo bioavailability in rats. Eur. J. Pharm. Biopharm. ,
67:96-105.

-